(Q46005833)

18 December 2017

title

Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. (English)

1 reference

18 December 2017

1 reference

Tomonori Kato

1

1 reference

18 December 2017

Akira Komiya

2

1 reference

18 December 2017

Hiroyoshi Suzuki

3

1 reference

18 December 2017

Takashi Imamoto

4

1 reference

18 December 2017

Takeshi Ueda

5

1 reference

18 December 2017

Tomohiko Ichikawa

6

1 reference

18 December 2017

publication date

1 May 2007

1 reference

18 December 2017

International Journal of Urology

published in

1 reference

18 December 2017

volume

14

1 reference

18 December 2017

issue

5

1 reference

18 December 2017

page(s)

416-421

1 reference

18 December 2017

The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Baseline health-related quality of life in the management of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Defining an international research agenda for quality of life in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Fatigue in patients with prostate cancer receiving hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Muscle strength in healthy white and Asian subjects: the relationship of quadriceps maximum voluntary contraction to age, sex, body build and vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Quality-of-life outcomes in long-term survivors of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

Patient and Community Preferences for Outcomes in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1442-2042.2007.01748.X

10.1111/J.1442-2042.2007.01748.X

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

PubMed ID

17511724

1 reference

18 December 2017